Azenta (AZTA) Initiation of Coverage
Investment Summary
- Azenta, Inc. has transformed into a pure-play life sciences company, exiting the semiconductor business in 2022 and focusing on Sample Management Solutions (SMS) and Multiomics.
- Over the last three years, Azenta executed operational turnarounds, divested non-core assets (notably B Medical Systems), and aggressively returned capital via share repurchases ($1.5B completed).
- Revenue growth has been resilient in core segments, with SMS and Multiomics outperforming industry trends, though capital equipment and North American Multiomics remain challenged.
- Margin expansion efforts are ongoing, with adjusted EBITDA margins improving through cost actions and restructuring, but profitability remains pressured by segment softness and execution gaps.
- The balance sheet is robust, with substantial cash reserves ($529M as of Q3 2026), no debt, and flexibility for M&A and further capital returns.
- Key risks include persistent execution issues in Multiomics North America, macro headwinds (NIH funding, tariffs), and material weaknesses in internal controls.
Business Overview
Azenta, Inc. provides sample management and multiomics solutions to life sciences customers globally. The business is structured around two main segments:
- Sample Management Solutions (SMS): Automated stores, cryogenic storage, repository services, consumables, instruments, clinical biostores.
- Multiomics: Genomic services including next-generation sequencing (NGS), gene synthesis, Sanger sequencing, and related services.
B Medical Systems (vaccine cold chain) was divested in FY2025 and is now reported as discontinued operations.
Financial Snapshot: Key Material Information (Fiscal Years)
| Fiscal Year Ended | Revenue ($M) | Revenue Growth (%) | Gross Margin (%) | Operating Loss ($M) | Net Income (Loss) from Continuing Ops ($M) | Net Loss (Total, incl. Discontinued) ($M) | EPS (Diluted, Continuing Ops) | Cash & Equiv. ($M) | Marketable Securities ($M) | Stockholders’ Equity ($M) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 593.8 | +3.6 | 45.5 | -26.8 | 24.5 | -55.8 | 0.53 | 283.5 | 262.7 | 1,727.0 |
| 2024-09-30 | 573.4 | +4.0 | 44.4 | -51.3 | -24.4 | -164.9 | -0.46 | 290.1 | 200.6 | 1,767.8 |
| 2023-09-30 | 551.5 | - | 43.4 | -61.2 | -8.0 | -14.6 | -0.12 | - | - | - |
Segment Revenue and Operating Income/Loss (Fiscal Years)
Segment Revenue ($M)
| Segment | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Sample Management Solutions | 324.6 | 318.9 | 303.2 |
| Multiomics | 269.2 | 254.6 | 248.3 |
| Total | 593.8 | 573.4 | 551.5 |
Segment Adjusted Operating Income (Loss) ($M)
| Segment | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Sample Management Solutions | 27.6 | 11.1 | -2.3 |
| Multiomics | -11.9 | -7.7 | -13.3 |
| Total | 15.6 | 3.4 | -15.6 |
Quarterly Financials: Most Recent Actuals (Q1-Q3 FY2026)
| Quarter | Revenue ($M) | Organic Growth (%) | Adj. EBITDA Margin (%) | Free Cash Flow ($M) | Cash & Equiv. ($M) | Non-GAAP EPS ($) |
|---|---|---|---|---|---|---|
| Q3 2026 | 161 | +9 | 11.4 | -5 | 529 | 0.16 |
| Q2 2026 | 145 | -3 | 5.4 | 5 | 565 | -0.04 |
| Q1 2026 | 149 | -1 | 8.5 | 15 | 571 | 0.09 |
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Revenue growth in both core segments (Sample Management Solutions +1.8%, Multiomics +5.8% YoY in FY2025) | Material weaknesses in internal controls over financial reporting remain unremediated as of FY2025 |
| Gross margin improvement to 45.5% in FY2025 (+110 bps YoY) | Continued operating losses, though narrowing; total net loss in FY2025 was -$55.8M |
| Turnaround to positive net income from continuing operations in FY2025 ($24.5M vs. -$24.4M in FY2024) | Significant losses from discontinued operations (B Medical Systems: -$80.2M in FY2025) |
| Strong balance sheet: $283.5M cash, $262.7M marketable securities, no debt as of FY2025 | Ongoing restructuring and transformation costs; restructuring charges of $5.2M in FY2025 |
| International revenue growth (39% of total in FY2025, up from 36% in FY2024) | Exposure to macroeconomic, geopolitical, and regulatory risks (China, tariffs, AI/data privacy, etc.) |
| Focused portfolio after divestiture of non-core businesses | Competitive pressures in both segments; Multiomics segment remains unprofitable |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Full focus on core segments after the B Medical Systems divestiture | Residual losses or liabilities from discontinued operations |
| Further margin expansion through operational efficiencies and cost management | Failure to remediate internal control weaknesses, leading to regulatory or investor confidence issues |
| Acceleration in Multiomics growth, especially Next Generation Sequencing services | Regulatory changes impacting gene synthesis, data privacy, or cross-border data transfer (e.g., Bulk Transfer Rule) |
| Successful execution of transformation initiatives and restructuring | Geopolitical/tariff risks, especially related to China and supply chain |
| Potential M&A or strategic partnerships in life sciences | Increased competition or pricing pressure in core markets |
Top Questions to Ask Before Investing
- Internal Controls: What is the timeline and plan for remediating the identified material weaknesses in internal controls over financial reporting? How confident is management in achieving effective controls in FY2026?
- Discontinued Operations: What residual financial impact remains from the B Medical Systems divestiture?
- Sustainability of Profitability: Can the company sustain and grow its positive net income from continuing operations, or was FY2025 an outlier due to one-time tax benefits?
- Multiomics Segment Path to Profitability: What is the strategy to bring the Multiomics segment to profitability, given continued operating losses?
- Competitive Positioning: How does Azenta differentiate itself from major competitors (e.g., Hamilton, Thermo Fisher, BGI Genomics, Eurofins) in both Sample Management and Multiomics?
- Exposure to China and Geopolitical Risks: How significant is the company’s exposure to China, and what steps are being taken to mitigate risks from tariffs, regulatory changes, and the Bulk Transfer Rule?
- Capital Allocation: With a strong balance sheet and no current buyback authorization, what are the priorities for capital deployment (organic investment, M&A, return to shareholders)?
- Transformation and Restructuring: What are the expected cost savings and timeline for the ongoing transformation and restructuring initiatives?
- Growth Drivers: What are the key growth drivers for each segment over the next 2-3 years, and how is management positioning to capture them?
- Customer Concentration and Retention: Are there any risks related to customer concentration, and what is the company’s approach to customer retention and expansion?
